<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liraglutide is a Glucagon like <z:chebi fb="7" ids="16670">Peptide</z:chebi>-1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, which stimulates GLP-1 receptors and consequently leads to various cardio-metabolic and glycemic improvements in individuals with Type 2 <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>It is administered once daily as a subcutaneous injection and has been extensively studied in randomized placebo and active comparator studies demonstrating favorable effects on glycemic control and weight reduction </plain></SENT>
<SENT sid="2" pm="."><plain>This short review summarizes the role and practical use of this agent in the context of efficacy and safety information obtained during clinical trials </plain></SENT>
</text></document>